Olema Pharmaceuticals (OLMA) Current Leases (2021 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Current Leases of $956000.0 for Q1 2026, down 6.73% year-over-year from $1.0 million in Q1 2025, and down 14.95% quarter-over-quarter from $1.1 million in Q4 2025.
Powered by 
Analysis
Olema Pharmaceuticals (OLMA) Current Leases (2021 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Current Leases for 6 consecutive years, with $956000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases fell 6.73% year-over-year to $956000.0; the TTM figure through Mar 2026 stood at $956000.0 (down 6.73% YoY), while the FY2025 annual figure was $1.1 million, down 4.1% from the prior year.
- Current Leases slipped to $956000.0 in Q1 2026 per OLMA's latest filing, from $1.1 million in the prior quarter.
- Across five years, Current Leases topped out at $1.2 million in Q4 2024 and bottomed at $798000.0 in Q2 2023.
- Historically, Current Leases has averaged $1.0 million across 5 years, with a median of $1.1 million in 2024.
- Annual changes were most pronounced in 2023 — Current Leases declined 25.97% — and 2024, when it surged 38.22%.
- Olema Pharmaceuticals' Current Leases stood at $1.0 million in 2022, then decreased by 2.66% to $988000.0 in 2023, then climbed by 18.62% to $1.2 million in 2024, then declined by 4.1% to $1.1 million in 2025, then decreased by 14.95% to $956000.0 in 2026.
- Business Quant data shows OLMA's Current Leases at $956000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Olema Pharmaceuticals | 1.13 Bn | 1.13 Bn | - | 660,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 660,000.00 |
| Mar 31, 2026 | 956,000.00 |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.03 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 988,000.00 |
| Sep 30, 2023 | 924,000.00 |
| Jun 30, 2023 | 798,000.00 |
| Mar 31, 2023 | 908,000.00 |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 1.08 Mn |
| Mar 31, 2022 | 881,000.00 |
| Dec 31, 2021 | 931,000.00 |